No Data
Cyfuse Biomedical KK: Financial Report - Term 15 (2024/01/01 - 2024/12/31)
Cyfuse Biomedical KK: Confirmation
Mirai Works, Cell Seed and others.
The acquisition of shares in Sky 365, which is involved in MSP (operations, monitoring, maintenance) business and Software Development related to Beex Cloud. <4594> Brightpath has revised its Financial Estimates, projecting an operating loss of 1.114 billion yen for this term, compared to 0.925 billion yen previously. <4598> A clinical phase 2/3 comparative trial of DELTA-PDFP-17729 has begun. <4881> A large exercise of the 12th subscription rights of Fanpepp with price adjustment clauses will start on the 17th, with the number of shares to be delivered being 85.
Saifuze rebounds after seven days, viewing the lifting of regulatory measures on Margin Trading and the reduction of trading burdens as material.
Saifuse <4892.T> has rebounded for the first time in seven days, reaching a peak of 20 yen higher at 986 yen. The Tokyo Stock Exchange announced after the close on the previous week’s Friday, the 21st, that they would lift the margin trading restrictions on the company's stock transactions starting from the trades on the 24th. This was seen as a reduction in trading burdens. The Tokyo Stock Exchange had previously implemented a measure to raise the deposit margin rate for new Sell and Buy transactions through Margin Trading to over 50% (with at least 20% in cash) starting from the trades on February 25.
PHCHD has developed a new production technology for the commercialization of 3D cell products in collaboration with Cyfuse.
PHCHD <6523.T> announced on the 19th that its subsidiary, PHC, has developed new production technology based on a business alliance and joint research with Saifuze <4892.T> aimed at commercialization in the fields of regenerative and cellular medicine. According to the company, this technology enables real-time monitoring of the quality of "living cells" and "three-dimensional cells," which has been technically challenging until now, contributing to the improvement of the quality of cell products and stable manufacturing.
Express News | [Change Report] SBI Ventures reports a decrease in Shareholding of Saifuze (4892.JP) to 9.99%.